Hyperprogressive disease (HPD) is a novel pattern of response during immunotherapy treatment. Several retrospective studies have evaluated its prevalence among various cancer types and, in particular, in nonsmall cell lung cancer patients, based on different definition criteria. If HPD is a just a typical phenomenon of immunotherapy is still an unsolved concern. This paper summarized the available data about HPD in other cancer treatments. Hyperprogressive disease (HPD) is a novel pattern of response during immunotherapy treatment. Several retrospective studies have evaluated its prevalence among various cancer types and, in particular, in non-small cell lung cancer patients, based on different definition criteria. If HPD is a just a typical phenomenon of immunotherapy is still an unsolved concern. This paper summarized the available data about HPD in other cancer treatments.

Is hyperprogressive disease a specific phenomenom of immunotherapy? / Brambilla, M., Lo Russo, G., Ferrara, R., Manglaviti, S., Garassino, M., Occhipinti, M.. - In: EXPLORATION OF TARGETED ANTI-TUMOR THERAPY. - ISSN 2692-3114. - 9:5(2020), pp. 1143-1161. [10.37349/etat.2020.00027]

Is hyperprogressive disease a specific phenomenom of immunotherapy?

FERRARA R;
2020-01-01

Abstract

Hyperprogressive disease (HPD) is a novel pattern of response during immunotherapy treatment. Several retrospective studies have evaluated its prevalence among various cancer types and, in particular, in nonsmall cell lung cancer patients, based on different definition criteria. If HPD is a just a typical phenomenon of immunotherapy is still an unsolved concern. This paper summarized the available data about HPD in other cancer treatments. Hyperprogressive disease (HPD) is a novel pattern of response during immunotherapy treatment. Several retrospective studies have evaluated its prevalence among various cancer types and, in particular, in non-small cell lung cancer patients, based on different definition criteria. If HPD is a just a typical phenomenon of immunotherapy is still an unsolved concern. This paper summarized the available data about HPD in other cancer treatments.
2020
Inglese
9
5
1143
1161
19
Pubblicato
Esperti anonimi
Internazionale
Goal 3: Good health and well-being
No
Is hyperprogressive disease a specific phenomenom of immunotherapy? / Brambilla, M., Lo Russo, G., Ferrara, R., Manglaviti, S., Garassino, M., Occhipinti, M.. - In: EXPLORATION OF TARGETED ANTI-TUMOR THERAPY. - ISSN 2692-3114. - 9:5(2020), pp. 1143-1161. [10.37349/etat.2020.00027]
none
6
info:eu-repo/semantics/article
262
Brambilla, Marta; Lo Russo, Giuseppe; Ferrara, R; Manglaviti, Sara; Garassino, Marina; Occhipinti, Mario
1 Contributo su Rivista::1.1.3. Articolo in Rivista - Editorial, Comment, Reply
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/176290
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? ND
social impact